Companies /Healthcare
Krystal Biotech Inc
NASDAQ: KRYS Biotechnology
$296.46
▼ $1.44 (−0.48%) today
Markets open · 4:03pm ET

Krystal Biotech (KRYS) Q3 2026 Earnings

Reported Nov 2, 2026, 7:07am ET · SEC source
$2.05
Beat +6.88%
EPS · est. $1.92 GAAP
$127.3M
Beat +0.63%
Revenue · est. $126.5M
1 quarter
Consecutive EPS beats

How Did KRYS Stock React to Q3 2026 Earnings?

−10.95%
Day of report
+3.09%
Next session
+2.42%
One week

Did KRYS Beat Earnings? Q3 2026 Results

Yes. Krystal Biotech reported Q3 2026 earnings of $2.05 a share on Nov 2, 2026, beating the $1.92 consensus estimate by 6.9%. Revenue was $127.3M against a $126.5M estimate.

Krystal Biotech delivered a clean beat across both top and bottom lines in the third quarter of 2026, with VYJUVEK's continued commercial momentum carrying the gene therapy company ahead of Wall Street expectations. GAAP earnings per share came in at $2.05, clearing the $1.92 consensus estimate by 6.88%, while revenue of $127.34 million edged past the $126.54 million consensus by 0.63% and grew 30.2% year over year. The sole driver of both figures was VYJUVEK, the company's topical gene therapy for dystrophic epidermolysis bullosa, which generated $127.30 million in global net product revenue at a 94% gross margin and pushed cumulative sales since launch to $1.10 billion. More than 760 U.S. reimbursement approvals have now been secured, and international expansion is progressing, with an Italian launch targeted for early 2027 and a Swiss marketing authorization filing planned before year end. The quarter also brought a $400.00 million share repurchase authorization, which management expects to deploy opportunistically over the next two years, signaling confidence in VYJUVEK's durable commercial trajectory.

Key Takeaways
  • VYJUVEK net product revenue up 30% year over year to $127.3 million
  • Gross margin of 94%
  • More than 760 U.S. reimbursement approvals for VYJUVEK
  • Steady expansion of the U.S. prescriber base
  • Growing patient starts in Germany, France and Japan
  • SG&A expense decreased to $33.7 million from $37.6 million

“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline.”

Krystal Biotech CEO, on the earnings call

What Is Krystal Biotech's Outlook?

FY2026 non-GAAP combined R&D and SG&A expense guidance, excluding stock-based compensation, is $155.0–$165.0 million. The company expects to: - Launch VYJUVEK in Italy in early 2027. - Receive a pricing decision in Spain later this year and in France no earlier than 2027. - Submit a Swiss marketing authorization application before year end. Expected pipeline milestones: - **KB111:** Interim HALITE-1 results by year end, an FDA meeting in Q1 2027, and a registrational study start in 2027. - **KB803:** Last patient visit in February 2027, with top-line results shortly after. - **KB801:** EMERALD-1 enrollment completion and top-line results in 2027. - **KB407:** Interim results in 1H 2027 and a registrational study initiation in 2027. - **KB408:** Interim results in 2027. - **KB707:** Enrollment of about 70 patients in the chemotherapy-combination cohort by mid-2027. - **KB304:** Phase 2 initiation in 2027. Share repurchases are expected to be made opportunistically over the next two years.

KRYS YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$40.0M$80.0M$120.0M$97.8M$127.3MRevenue$41.4M$71.1MOperating Income$79.4M$63.1MNet Income
$0$40.0M$80.0M$120.0MRevenueOperating IncomeNet Income
KRYS income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $127.3M $97.8M +30.2%
Operating Income $71.1M $41.4M +72.0%
Net Income $63.1M $79.4M −20.5%

KRYS Revenue by Segment

VYJUVEK$127.3M+30.0%

When Does Krystal Biotech Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.